Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies

Shots:

  • The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies
  • Luminary gets a non-exclusive license for TcBuster and will use it in the LMY-920 program. Luminary plans to file an IND with the FDA in late 2021
  • The license agreement will allow Bio-Techne to increase its presence in the cell and gene therapy market

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Owler

The post Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies first appeared on PharmaShots.

Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan

Shots:

  • Chugai gets exclusive development and commercializing rights for AT-527 in Japan
  • Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US
  • AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in a P-II study in patients with moderate COVID-19 requiring hospitalization and patients with mild to mod. COVID-19 who are not hospitalized. A P-III study is expected to start in the H1’21

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Wikipedia

The post Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan first appeared on PharmaShots.

P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages

Shots:

  • Rhinostics plans to register the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing for detection of SARS-CoV-2 infection
  • Rhinostics Standard Nasal Swab is a polypropylene collection device developed in partnership with P&G for COVID-19 testing which provides sample concentration of up to 30-fold over other swabs in viral transport media
  • The swab increases COVID testing efficiencies being applicable to broader respiratory viral, bacterial, and genetic testing using the PCR and NGS

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Packaging Europe

The post P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages first appeared on PharmaShots.

MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US

Shots:

  • Aquestive will receive upfront, milestones, royalties on net sales for Exservan (oral film formulation) in the US and will earn revenue pursuant to the exclusive supply agreement
  • MTPA to commercialize Exservan in the US while Aquestive will serve as the exclusive sole manufacturer and supplier for the product
  • Exservan is an oral film formulation of riluzole, expected to be available in the mid of 2021

Click here ­to­ read full press release/ article | Ref: MTPA | Image: PR Newswire

The post MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US first appeared on PharmaShots.

Sanofi Signs a License Agreement with Biond for BND-22

Shots:

  • Biond to receive $125M up front in cash and will be eligible to receive ~$1B+ as development, regulatory & commercial milestones, along with royalties on sales of the therapy
  • Biond will lead P-Ia study of BND-22, assessing its safety & tolerability as a single agent and in combination with approved cancer therapies as well as exploring potential associations b/w BND-22 anti-tumor activity, select tumor and blood-based biomarkers. Sanofi will be further responsible for clinical development and commercialization of BND-22
  • BND-22 is a humanized IgG4, antagonist Ab targeting ILT2 receptor in development for solid tumors. The first P-Ia study of BND-22 is anticipated to start by mid-2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: 20 Minutes

The post Sanofi Signs a License Agreement with Biond for BND-22 first appeared on PharmaShots.

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

Shots:

  • Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory
  • 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions
  • Both the companies will share IND development costs. YBL-013 is a T cell bi-specific engager based on ALiCE platform technology and targets CD3 on T cell and PD-L1 on cancer cell

Click here ­to­ read full press release/ article | Ref: PRNasia | Image: Y-Biologics

The post Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China first appeared on PharmaShots.

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis

Shots:

  • The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos
  • Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804 in benign and malignant hematology indications
  • Following the exercising the global license option, Incyte to lead all activities and costs associated with research, development, and commercialization of the program

Click here ­to­ read full press release/ article | Ref: Businessiwre | Image: Businesswire

The post Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis first appeared on PharmaShots.

Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases

Shots:

  • Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases
  • Following the exercise of its options, Vertex will be responsible for further development and commercialization
  • Skyhawk will use its SkySTAR platform to discover & develop novel small molecule therapeutics that modulate RNA splicing targeting the serious disease

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Businesswire

The post Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases first appeared on PharmaShots.

Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research

Shots:

  • Precision to receive $100M upfront, $35M as an equity investment and will receive $420M as milestones/ product along with royalties on sales of licensed products emerges from the collaboration
  • Precision will lead to pre-clinical research and IND-enabling activities while Lilly will lead clinical development and commercialization and have the right to select up to 3 additional gene targets. Precision can co-fund clinical development of one product in exchange for an increased royalty rate on co-funded product sales
  • The agreement will utilize Precision’s ARCUS genome editing platform for the development of in vivo therapies for genetic disorders, focusing on DMD and two other undisclosed gene targets

Click here ­to­ read full press release/ article | Ref: Lilly | Image: KMS Lighthouse

The post Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research first appeared on PharmaShots.

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

Shots:

  • Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research, development, regulatory and commercial milestones along with royalties on sales of small molecules
  • The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global commercialization
  • The R&D collaboration builds on Lead Pharma’s expertise in the discovery, design, and optimization of small-molecule treatments

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

The post Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases first appeared on PharmaShots.

Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

Shots:

  • Seed Therapeutics to receive $10M upfront, $10M equity investment, ~$780M as pre/clinical development, regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration
  • Seed utilizes molecular glue protein degradation technology to develop potential new therapies
  • The agreement allows Seed to advance its platform to deliver new molecules targeting proteins that cause human diseases

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: Medium

The post Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies first appeared on PharmaShots.

Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test

Shots:

  • TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2
  • Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets, associated sequences and relevant data for the development and commercialization of IVD tests. In advance of exercising its option, Qiagen has the right to evaluate TScan’s discoveries
  • The targeted immunodominant were identified through the T-Scan TCR/Target discovery platform enabling the mapping of the specific epitopes in SARS-CoV-2

Click here­ to­ read full press release/ article | Ref: Businesswire | Image: TrialSite News

The post Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test first appeared on PharmaShots.

CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications

Shots:

  • LCB to receive $10 M as upfront, and up to $353.5M as cumulative milestone payments along with royalties on sales of LCB71. CStone get an exclusive global right to lead the development and commercialization of LCB71 outside the Republic of Korea
  • The collaboration adds the first ADC to CStone’s development pipeline, bolstering its precision medicine franchise with a new modality
  • LCB71 is a pre-clinical ADC targeting ROR1, having the potential to treat multiple cancer indications and has demonstrated efficacy and reduced toxicity in preclinical studies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Investopedia

The post CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications first appeared on PharmaShots.

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Shots:

  • Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423
  • During the option period, Molecular Partners will conduct a P-I study for MP0420, expected to initiate in Nov’2020, and perform all remaining preclinical work for MP0423 while Novartis will lead P-II & P-III study
  • Upon option exercise, Novartis will lead further development and commercialization activities while Molecular Partners will provide clinical supply during the development stage. MP0420 and MP0423 are potential medicines for the prevention & treatment of COVID-19, with the possibility of being manufactured at scale and the potential to bypass cold storage

Click here ­to­ read full press release/ article | Ref: Novartis | Image: M3 India

The post Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19 first appeared on PharmaShots.

Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies

Shots:

  • Chugai will receive an upfront, development milestone and royalties if the compound is launch as an approved Ab drug. Additionally, Chugai will receive a fee for technology access
  • Novo Nordisk to get the rights to use several Chugai Ab engineering technologies for their research activities and optional right for the development and marketing of therapeutic Abs
  • Novo Nordisk will utilize Chugai’s Ab engineering technologies targeting the unmet medical needs and create novel medicines

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Peter Boyle Solicitors

The post Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies first appeared on PharmaShots.

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Shots:

  • Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration
  • Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization activities for the products using the novel capsids
  • The collaboration leverages Dyno’s CapsidMap platform for the development of next-generation AAV vectors for CNS diseases and liver-directed therapies for the portfolio of both Roche and Spark

    Click here to­ read the full press release/ article | Ref: Dyno Therapeutics | Image: Oncology Nurse Advisor

The post Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~.8B first appeared on PharmaShots.

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

Shots:

  • Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002
  • BMS will be responsible for the development & commercialization of DF6002 and its related products, including strategic decisions, regulatory responsibilities, funding, and manufacturing
  • DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein, currently being evaluated in P-I/II study for patients with advanced solid tumors, which began in Jul’2020. Additionally, BMS plans to advance the research and development of DF6002 in oncology and hematology

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pharmashots

Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan

Shots:

  • Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW
  • Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in the licensed territory. The collaboration will initially focus on the development and commercialization of arfolitixorin as 1L treatment for mCRC patients and may extend it to other indications
  • Arfolitixorin is currently being evaluated in the ongoing global P-III AGENT study, conducted in the US, Canada, EU, Australia, and Japan. Isofol and Solasia plan to expand the study with additional sites in Japan while Isofol will remain as global sponsor of the study

Click here ­to­ read full press release/ article | Ref: Isofol | Image: CNN

AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis

Shots:

  • Redx to receive $17M in early payment by the time of successful commencement of a P-I study, $360M as development, a regulatory and commercial milestone along with royalties on sales of the RXC006
  • AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF
  • Redx continues to progress its lead oncology asset, RXC004 (porcupine inhibitor) targeting Wnt-driven tumors, currently being evaluated in P-I/II clinical trial, and RXC007, the oral Rock 2 inhibitor targeting fibrosis where first in human studies are expected in 2021

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: SoPosted